Covid: In both waves, 70% of patients above 40 years, says ICMR chief

Addressing media, ICMR Director General Balram Bhargava said there is no difference in deaths between first and second wave among hospitalised patients

Coronavirus
Patients with breathing problems are seen inside an ambulance waiting to enter a Covid-19 hospital for treatment | Photo: Reuters
Press Trust of India New Delhi
2 min read Last Updated : Apr 19 2021 | 4:28 PM IST

More than 70 per cent of Covid-19 patients over 40 years of age in both the waves and older population continues to be more vulnerable to the infection, the Centre said on Monday.

Addressing media, ICMR Director General Balram Bhargava said there is no difference in deaths between first and second wave among hospitalised patients, while the oxygen requirement is higher in second wave and ventilator requirement is not higher in the second wave.

Prevalence of shortness of breath is slightly higher in the second wave of Covid-19 but sore throat and dry cough and other symptoms were higher in the first wave, the Centre said on Monday.

"No difference in deaths between first and second wave among hospitalised patients. About 54.5 per cent patients require oxygen in second wave against 41.5 per cent in the first wave," he said.

"More than 70 per cent patients in both waves are more than 40 years old, only marginally higher proportion of younger patients. Higher proportion of asymptomatic patients in the second wave," he said, based on the study of 1,885 patients in second wave and 7,600 patients in the first wave.

NITI Aayog Member (Health) V K Paul said in the first wave 31 per cent patients were aged less than 30 years, this time it is up to 32 per cent.

"Essentially there is no difference," Paul said.

Bhargava appealed that wastage of oxygen must not happen and it should be rationalised.

Paul added that remdesivir must be used on hospitalised patients in moderate stages of illness on oxygen and it is not to be used in home settings.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

Topics :CoronavirusCoronavirus TestsCoronavirus Vaccine

First Published: Apr 19 2021 | 4:28 PM IST

Next Story